Floatz logo

Solu-Cortef

Recurrent Childhood Acute Lymphoblastic Leukemia

Children's Oncology GroupPhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
89/ 100

Competitive context

70 Active assets in the Recurrent Childhood Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 3BBB
MERCAPTOPURINE ANHYDROUS
Children's Oncology Group
Phase 3BBB
FILGRASTIM
St. Jude Children's Research Hospital
Phase 3BBB
Cyclophosphamide
St. Jude Children's Research Hospital
Phase 3BBB
Cytosin-Arabinosid
Children's Oncology Group
Phase 3BBB

View all 50 →

Same molecule, other indications

Solu-Cortef is also rated in:

congenital adrenal hyperplasiaDormant
A
Indicative ·
81 / 100
View asset →
myelodysplastic syndromeDormant
BB
Indicative ·
68 / 100
View asset →
adrenocortical insufficiencyDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →